The Sunshine Act: What it means to you, what you need to do

Article

The Physician Payments Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

 

Washington-Before the fiscal year goes any farther, this may be a good time to review the newly implemented Physician Payments Sunshine Act, better known simply as the Sunshine Act, which went into effect August 1.

The Sunshine Act is meant to enhance transparency in relationships between the pharmaceutical and drug manufacturing industry and doctors or teaching hospitals. The act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

Manufacturers are required to collect and track payment, transfer, and ownership information. The compiled data is then submitted to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. Also, manufacturers and group purchasing organizations must report certain ownership interests held by doctors and their immediate family members.

Most of the information contained in the reports will be available on a public, searchable Web site starting Q4 2014. Doctors have the right to review their reports and challenge data that are false, inaccurate, or misleading.

To help doctors and the medical community at large navigate this new reporting obligation, the AMA offers a Toolkit for Physician Financial Transparency Reports . The Toolkit is a guide to complying with the process before your 2013 financial data is published online next year.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
© 2025 MJH Life Sciences

All rights reserved.